Central European Journal of Medicine

, Volume 4, Issue 3, pp 272–278 | Cite as

The concentration of uric acid in patients with metabolic syndrome and cardiovascular diseases

  • Jan Kowalski
  • Anna Krzemińska
  • Maciej Banach
  • Lucjan Pawlicki
  • Dorota Śliwczyńska-Rodziewicz
  • Marcin Barylski
Research Article


The association of elevated serum uric acid (hyperuricemia, gout) with the presence of classical coronary risk factors and coronary artery disease (CAD) or myocardial infarction (MI) has been analysed in many epidemiological studies. Numerous studies have revealed that hypertension, high body mass index (BMI), lipid disorders (especially raised triglyceride (TG) levels and low high dense lipoprotein cholesterol (HDL-C) level), and increased creatinine or insulin levels have caused hyperuricemia. Gout has often occurred with typical disorders for the metabolic syndrome X. Significant correlation of the serum uric level and the CAD presence and severity of coronary atherosclerosis confirmed by coronary angiography has been observed in women. Hyperuricemia has also indirect influence on progress of CAD by physical activity restriction, what causes sedentary mode of life and lead to obesity. Therefore, we conducted our study in order to estimate uric acid levels in patients with metabolic syndrome and coexisting cardiovascular system diseases.


Hyperuricemia Metabolic syndrome Cardiovascular diseases 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. [1]
    Expert Panel on Detection Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), JAMA, 2001, 285, 2486–2497CrossRefGoogle Scholar
  2. [2]
    Ford E.S., Giles W.H., A comparison of the prevalence of the metabolic syndrome using two proposed definitions, Diabetes Care, 2003, 26, 575–581PubMedCrossRefGoogle Scholar
  3. [3]
    International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome, April, 2005:
  4. [4]
    Pearson T.A., Blair S.N., Daniels S.R., Eckel R.H., Fair J.M., Fortmann S.P., AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee, Circulation, 2002, 106, 388–391Google Scholar
  5. [5]
    Grundy S.M., Hansen B., Smith S.C., Cleeman J.I., Kahn R.A., American Heart Association: National Heart, Lung, and Blood Institute: American Diabetes Association. Clinical management of metabolic syndrome report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management, Circulation, 2004, 109, 551–556Google Scholar
  6. [6]
    Isomaa B., Almgren P., Tuomi T., Forsen B., Lahti K., Nissen M., Cardiovascular morbidity and mortality associated with the metabolic syndrome, Diabetes Care, 2001, 24, 683–689PubMedCrossRefGoogle Scholar
  7. [7]
    Lakka H.M., Laaksonen D.E., Lakka T.A., Niskanen L.K., Kumpusalo E., Tuomilehto J., The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men, JAMA, 2002, 288, 2709–2716PubMedCrossRefGoogle Scholar
  8. [8]
    Pasceri V., Willerson J.T., Yeh T., Direct proinflammatory effect of C-reactive protein on human endothelial cells, Circulation, 2000, 102, 2165–2168PubMedGoogle Scholar
  9. [9]
    Yarnell J.W., Sweetnam P.M., Rumley A., Lowe G.D., Lifestyle and hemostatic risk factors for ischemic heart disease. The Caerphilly Study, Arterioscler. Thromb. Vasc. Biol., 2000, 20, 271–279Google Scholar
  10. [10]
    Doehner W., Schoene N., Rauchhaus M., Leyva-Leon F., Pavitt D.V., Reaveley D.A., Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies, Circulation, 2002, 105, 2619–2624PubMedCrossRefGoogle Scholar
  11. [11]
    Frohlich E.D., Uric acid: a risk factor for coronary heart disease, JAMA, 1993, 270, 354–359CrossRefGoogle Scholar
  12. [12]
    Stanton J.R., Freis E.D., Serum uric acid concentration in essential hypertension, Proc. Soc. Exp. Biol. Med, 1947, 66, 193–194Google Scholar
  13. [13]
    Sudstrőm J., Sullivan L., D’Agostino R.B., Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence, Hypertension, 2005, 45, 28–33Google Scholar
  14. [14]
    Alper A.B. Jr., Chen W., Yau L., Srinivasan S.R., Berenson G.S., Hamm L.L., Childhood uric acid predicts adult blood pressure: the Bogalusa Heart Study, Hypertension, 2005, 45, 34–38PubMedGoogle Scholar
  15. [15]
    Freedeman D.S., Williamson D.F., Grunter E.W., Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiologic Follow-up Study, Am. J. Epidemiol., 1995, 141, 637–644Google Scholar
  16. [16]
    Kostka-Jeziorny K., Tykarski A., Związek hiperurykemii z innymi czynnikami ryzyka sercowo-naczyniowego u pacjentów z pierwotnym, nieleczonym nadciśnieniem tętniczym w populacji badania RISK, Nadciśnienie Tętnicze, 2008, 12, 190–199 (in Polish)Google Scholar
  17. [17]
    Berkowitz D., Gout, hyperlipidemia and diabetes interrelationships, JAMA, 1966, 197, 117–122CrossRefGoogle Scholar
  18. [18]
    Mikkelsen W.M., The possible associations of hyperuricemia and/or gout with diabetes mellitus, Arth. Reum., 1965, 8, 853–863CrossRefGoogle Scholar
  19. [19]
    Reed D., Labarthe D., Stallones R., Epidemiologic studies of serum uric acid levels among Micronesian, Arth. Rheum., 1972, 15, 38–43Google Scholar
  20. [20]
    Myers A.R., Relationship of serum uric acid to risk factors in coronary heart disease, Am. J. Med., 1968, 45, 520–534PubMedCrossRefGoogle Scholar
  21. [21]
    Yano K., Rhoads G., Kagan A., Epidemiology of serum uric acid among 8000 Japanese men in Hawaii, J. Chronic. Dis., 1977, 30, 171–184PubMedCrossRefGoogle Scholar
  22. [22]
    Klein R., Klein B., Cornoni J., Serum uric acid:its relationship to coronary heart disease, risk factors and cardiovascular disease, Arch. Intern. Med., 1973, 132, 401–409PubMedCrossRefGoogle Scholar
  23. [23]
    Herman J.B., Medalie J.H., Groen J.J., Diabetes prevalence and serum uric acid. Observation among 10000 men in survey of ischemic heart disease in Israel, Diabetes, 1967, 16, 858–868Google Scholar
  24. [24]
    Herman J.B., Keyman A., Hyperglycemia and uric acid, Isr. J. Med. Sci., 1969, 5, 1048–1053PubMedGoogle Scholar
  25. [25]
    Padova J., Patchefsky A., Onesti G., The effect of glucose loads on renal uric acid excretion in diabetic patients, Metabolism., 1964, 13, 507–511PubMedCrossRefGoogle Scholar
  26. [26]
    Bedir A., Topbas M., Tanyeri F., Alvur M., Arik N., Leptin might be a regulator of serum uric acid concentration in humans, Jpn. Heart J., 2003, 44, 527–536PubMedCrossRefGoogle Scholar
  27. [27]
    Modan M., Halkin H., Karasik A., Elevated serum uric acid — a face of hyperinsulinaemia. Diabetologia, 1987, 30, 713–719PubMedCrossRefGoogle Scholar
  28. [28]
    Patel P.D., Arora R.R., Uric acid and xanthine oxidase: perspectives in chronic heart failure, Arch. Med. Sci., 2008, 4, 219–225Google Scholar
  29. [29]
    Bickel C., Rupprecht H.J., Blankenberg S., Rippin G., Hafner G., Daunhauer A., Hofmann K.P., Meyer J., Serum uric acid as an independent predictor of mortality in patients with angiographically proven coronary artery disease., Am. J. Cardiol., 2002, 89, 12–17PubMedCrossRefGoogle Scholar
  30. [30]
    Okrasa-Bylica A., Paradowski A., Matysek J., Czubek U., Piwowarska W., Sex hormone plasma levels in premenopausal women with coronary heart disease, Cardiol. J. 2006, 13, 423–426Google Scholar
  31. [31]
    Agamah E.S., Srinivasan S.R., Weber L.S., Berenson G.S., Serum uric acid and its relation to cardiovascular disease risk factors in children and young adults from a biracial community: the Bogalusa Heart Study, J. Lab. Clin. Med., 1991, 118, 241–249PubMedGoogle Scholar
  32. [32]
    Rathmann W., Funkhouser E., Dyer A.R., Roseman J.M., Relations of hyperuricemia with the various components of the insulin resistence syndrome in young black and white adults: the CARDIA study. Coronary artery risk development in young adults, Ann. Epidemiol., 1998, 8, 250–261PubMedCrossRefGoogle Scholar
  33. [33]
    Matsuura F., Yamashita S., Nakamura T., Effect of visceral fat accumulation on uric acid metabolism in male obese subjects: visceral fat obesity is linked more closely to overproduction of uric acid than subcutaneous fat obesity, Metabolism, 1998, 47, 929–933PubMedCrossRefGoogle Scholar
  34. [34]
    Bonora E., Targher G., Zenere M.B., Relationship of uroic acid concentration to cardiovascular risk factors in young men. Role of obesity and central fat distribution. The Verona Young Men Atherosclerosis Risk Factors Study, Int. J. Obes., 1996, 20, 975–980Google Scholar
  35. [35]
    Feig D.I., Johnson R.J., Hyperuricemia in childhood primary hypertension, Hypertension, 2003, 42, 247–252PubMedCrossRefGoogle Scholar
  36. [36]
    Tykarski A., Mechanizm hiperurykemii oraz ocena wpływu leków hipotensyjnych na transport kwasu moczowego i jego prekursorów w nefronie w nadciśnieniu tętniczym pierwotnym. Praca habilitacyjna. Akademia Medyczna im. Karola Marcinkowskiego w Poznaniu. Poznań 1997 (in Polish)Google Scholar
  37. [37]
    Zalokar J., Lelllouch J., Claude J.R., Kuntz D., Epidemiology of serum uric acid and gout in Frenchmen, J. Chronic. Dis., 1974, 27, 59–75PubMedCrossRefGoogle Scholar
  38. [38]
    Lee J., Sparrow D., Vokonas S., Uric acid and Coronary Heart Disease Risk: Evidence for a Role of Uric acid in the Obesity-Insulin Resistance Syndrome, Am. J. Epidemiol., 1995, 142, 3–8Google Scholar
  39. [39]
    Zoccali C., Maio R., Mallamaci F., Sesti G., Perticone F., Urid acid and endothelial dysfunction in essentiali hypertension, J. Am. Soc. Nephrol., 2006, 17, 1466–1471PubMedCrossRefGoogle Scholar
  40. [40]
    Perlstein T.S., Gumieniak O., Hopkins P.N., Murphey L.J., Brown N.J., Williams G.H., Uric acid and the state of the intrarenal renin-angiotensin system in humans, Kidney Int., 2004, 66, 1465–1470PubMedCrossRefGoogle Scholar
  41. [41]
    Doehner W., Anker S.D., Filippatos G.S., Uric acid in chronic heart failure: marker or therapeutic target? Arch. Med. Sci., 2008, 4, 226–228Google Scholar
  42. [42]
    Barylski M, Kowalczyk E, Banach M, Ciecwierz J, Pawlicki L, Kowalski J., Plasma Total Antioxidant Activity in Comparison With Plasma NO and VEGF Levels in Patients With Metabolic Syndrome. Angiology, 2009, 60, 87–92PubMedCrossRefGoogle Scholar
  43. [43]
    Banach M, Rysz J, Goch A, Mikhailidis DP, Rosano GM., The role of trimetazidine after acute myocardial infarction. Curr. Vasc. Pharmacol., 2008, 6, 282–291PubMedCrossRefGoogle Scholar
  44. [44]
    Boncler M., Gresner P., Nocun M., Rywaniak J., Dolnik M., Rysz J., et al., Elevated cholesterol reduces acetylsalicylic acid-mediated platelet acetylation, Biochim. Biophys. Acta., 2007, 1770, 1651–1659PubMedGoogle Scholar

Copyright information

© © Versita Warsaw and Springer-Verlag Berlin Heidelberg 2009

Authors and Affiliations

  • Jan Kowalski
    • 1
  • Anna Krzemińska
    • 1
  • Maciej Banach
    • 2
  • Lucjan Pawlicki
    • 1
  • Dorota Śliwczyńska-Rodziewicz
    • 1
  • Marcin Barylski
    • 1
  1. 1.Department of Internal Diseases and Cardiological RehabilitationMedical University of LodzLodzPoland
  2. 2.Department of HypertensionMedical University of LodzLodzPoland

Personalised recommendations